J. Goldman & Co’s AbbVie ABBV Stock Holding History

J. Goldman & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-35,000	Closed	-$4.72M	–	350
2023 Q2	$4.72M	Buy	+35,000	New	+$5.13M	0.17%	142
2022 Q4	–	Sell	-50,000	Closed	-$6.71M	–	357
2022 Q3	$6.71M	Buy	+50,000	New	+$7.17M	0.32%	93
2019 Q1	–	Sell	-13,000	Closed	-$1.2M	–	262
2018 Q4	$1.2M	Buy	+13,000	New	+$1.14M	0.09%	173

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Goldman & Co's ABBV Position: Q4 2023 in Review

J. Goldman & Co sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 178,591 shares — an estimated $26M sold.

J. Goldman & Co first reported a position in ABBV in Q3 2022 and held it in 3 quarters. The position peaked at $27.3M in Q2 2023. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

J. Goldman & Co reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 178,591 AbbVie shares in Q4 2023, an estimated $26M.
J. Goldman & Co first reported a position in AbbVie in Q3 2022 and held it in 3 quarters.
J. Goldman & Co's AbbVie position peaked at $27.3M in Q2 2023.
3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.